Piper Sandler Reaffirms Optimism on Compass Therapeutics (CMPX) Amid Trial Update

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the must-buy penny stocks to invest in. On August 18, Piper Sandler reiterated its Overweight rating and $12.00 price target for Compass Therapeutics, citing strong performance and promising clinical developments. The stock has surged 131% over the past year, reflecting investor confidence in the company’s oncology pipeline.

The COMPANION-002 trial’s secondary endpoint analysis is delayed to Q1 2026 due to slower survival events in second-line biliary tract cancer. Piper Sandler sees this as a possible positive, noting that nearly 50% crossover to treatment may boost tovecimig’s survival data.

Compass expects full CTX-8371 data in Q4 2025, boosting its pipeline momentum. Backed by a solid balance sheet and progressing trials, the company is well-positioned for ongoing growth in oncology.

Compass Therapeutics, Inc. (NASDAQ:CMPX) is a U.S.-based clinical-stage biopharmaceutical company focused on oncology. It develops antibody-based therapies, with lead candidates like tovecimig—a bispecific antibody targeting DLL4 and VEGF pathways—aimed at treating aggressive cancers.

While we acknowledge the potential of CMPX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 6 Best Railroad Stocks to Buy Right Now and 11 Best Very Cheap Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.